Previous Article | Next Article 
Journal of Clinical Microbiology, January 1998, p. 94-99, Vol. 36, No. 1
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparison of Performance and Cost-Effectiveness of
Direct Fluorescent-Antibody, Ligase Chain Reaction, and PCR Assays for
Verification of Chlamydial Enzyme Immunoassay Results for Populations
with a Low to Moderate Prevalence of Chlamydia
trachomatis Infection
Deborah
Dean,1,*
Dennis
Ferrero,2 and
Michael
McCarthy3
Departments of Medicine and the Francis I. Proctor Foundation, University of California at San Francisco School
of Medicine, San Francisco,1 and
San
Joaquin County Regional Public Health
Laboratory, Stockton,2 California, and
Diagnostic Laboratory, Auckland, New Zealand3
Received 4 August 1997/Returned for modification 12 September
1997/Accepted 10 October 1997
Many laboratories use a commercial enzyme immunoassay (EIA) with
verification testing to diagnose Chlamydia trachomatis
infections in an effort to contain costs. This study was designed to
compare the performance and cost-effectiveness of direct
fluorescent-antibody assay (DFA), commercial PCR, and ligase chain
reaction (LCR) for the verification of EIA results. Cervical specimens
were screened by EIA. DFA, PCR, and LCR were compared as verification
tests for EIA-reactive specimens and negative greyzone (NGZ) specimens at 50% below the cutoff value. These samples were also tested by
in-house PCR, which was used in the analysis of verification results. A
total of 477 (7%) of 6,571 samples were reactive or within the NGZ.
EIA results with verification by DFA testing (EIA/DFA results) agreed
with 93% of the true results compared with 97% for EIA/PCR results
for one set of 242 samples; there was 97% agreement with true results
for EIA/DFA results versus 95% for EIA/LCR results for another set of
235 samples. Ten samples were false positive by LCR. Time and costs
were equivalent for EIA with the DFA, PCR, or LCR as the verification
test but were two- to threefold greater for PCR or LCR alone than for
EIA with verification. Since it is important to balance cost
containment with public health objectives, DFA, PCR, and LCR as EIA
verification tests for cervical samples offer acceptable sensitivities
and specificities at reasonable cost for low- to moderate-risk
populations and therefore can be extended to a broader spectrum of
at-risk populations.
*
Corresponding author. Mailing address: University of
California at San Francisco School of Medicine, Box 0412, S-307, 513 Parnassus Ave., San Francisco, CA 94143-0412. Phone: (415) 476-4548. Fax: (415) 476-6085. E-mail: debd{at}itsa.ucsf.edu.
Journal of Clinical Microbiology, January 1998, p. 94-99, Vol. 36, No. 1
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Skidmore, S., Horner, P., Herring, A., Sell, J., Paul, I., Thomas, J., Caul, E. O., Egger, M., McCarthy, A., Sanford, E., Salisbury, C., Macleod, J., Sterne, J. A. C., Low, N., for the Chlamydia Screening Studies (ClaSS) Projec,
(2006). Vulvovaginal-Swab or First-Catch Urine Specimen To Detect Chlamydia trachomatis in Women in a Community Setting?. J. Clin. Microbiol.
44: 4389-4394
[Abstract]
[Full Text]
-
Horner, P., Skidmore, S., Herring, A., Sell, J., Paul, I., Caul, O., Egger, M., McCarthy, A., Sanford, E., Salisbury, C., MacLeod, J., Sterne, J., Low, N., for the Chlamydia Screening Studies (ClaSS) Group,
(2005). Enhanced Enzyme Immunoassay with Negative-Gray-Zone Testing Compared to a Single Nucleic Acid Amplification Technique for Community-Based Chlamydial Screening of Men. J. Clin. Microbiol.
43: 2065-2069
[Abstract]
[Full Text]
-
Hu, D., Hook, E. W. III, Goldie, S. J.
(2004). Screening for Chlamydia trachomatis in Women 15 to 29 Years of Age: A Cost-Effectiveness Analysis. ANN INTERN MED
141: 501-513
[Abstract]
[Full Text]
-
WATSON, E. J., TEMPLETON, A., RUSSELL, I., PAAVONEN, J., MARDH, P.-A., STARY, A., PEDERSON, B. S.
(2002). The accuracy and efficacy of screening tests for Chlamydia trachomatis: a systematic review. J Med Microbiol
51: 1021-1031
[Abstract]
[Full Text]
-
Battle, T. J., Golden, M. R., Suchland, K. L., Counts, J. M., Hughes, J. P., Stamm, W. E., Holmes, K. K.
(2001). Evaluation of Laboratory Testing Methods for Chlamydia trachomatis Infection in the Era of Nucleic Acid Amplification. J. Clin. Microbiol.
39: 2924-2927
[Abstract]
[Full Text]
-
Johnson, S. J., Green, D. H., Reed, D. A., Wood, L. S.
(2001). Semiautomation of Nucleic Acid-based Assays for Chlamydia trachomatis and Neisseria gonorrhoeae,. Clin. Chem.
47: 760-763
[Full Text]
-
Tanaka, M., Nakayama, H., Sagiyama, K., Haraoka, M., Yoshida, H., Hagiwara, T., Akazawa, K., Naito, S.
(2000). Evaluation of a new amplified enzyme immunoassay (EIA) for the detection of Chlamydia trachomatis in male urine, female endocervical swab, and patient obtained vaginal swab specimens. J. Clin. Pathol.
53: 350-354
[Abstract]
[Full Text]
-
Lauderdale, T.-L., Landers, L., Thorneycroft, I., Chapin, K.
(1999). Comparison of the PACE 2 Assay, Two Amplification Assays, and Clearview EIA for Detection of Chlamydia trachomatis in Female Endocervical and Urine Specimens. J. Clin. Microbiol.
37: 2223-2229
[Abstract]
[Full Text]
-
Herring, A., Caul, O., Paul, I., Horner, P.
(1999). Widening screening to detect Chlamydia trachomatis is more important than using DNA methods. BMJ
318: 1416-1416
[Full Text]
-
Ferrero, D. V., Meyers, H. N., Schultz, D. E., Willis, S. A.
(1998). Performance of the Gen-Probe AMPLIFIED Chlamydia Trachomatis Assay in Detecting Chlamydia trachomatis in Endocervical and Urine Specimens from Women and Urethral and Urine Specimens from Men Attending Sexually Transmitted Disease and Family Planning Clinics. J. Clin. Microbiol.
36: 3230-3233
[Abstract]
[Full Text]